Source:http://linkedlifedata.com/resource/pubmed/id/21757741
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
34
|
pubmed:dateCreated |
2011-8-22
|
pubmed:abstractText |
PTTG1, also known as securin, is an inactivating partner of separase, the major effector for chromosome segregation during mitosis. At the metaphase-to-anaphase transition, securin is targeted for proteasomal destruction by the anaphase-promoting complex or cyclosome, allowing activation of separase. In addition, securin is overexpressed in metastatic or genomically instable tumors, suggesting a relevant role for securin in tumor progression. Stability of securin is regulated by phosphorylation; some phosphorylated forms are degraded out of mitosis, by the action of the SKP1-CUL1-F-box protein (SCF) complex. The kinases targeting securin for proteolysis have not been identified, and mechanistic insight into the cause of securin accumulation in human cancers is lacking. Here, we demonstrate that glycogen synthase kinase-3? (GSK3?) phosphorylates securin to promote its proteolysis via SCF(?TrCP) E3 ubiquitin ligase. Importantly, a strong correlation between securin accumulation and GSK3? inactivation was observed in breast cancer tissues, indicating that GSK3? inactivation may account for securin accumulation in breast cancers.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Glycogen Synthase Kinase 3,
http://linkedlifedata.com/resource/pubmed/chemical/Neoplasm Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/SKP Cullin F-Box Protein Ligases,
http://linkedlifedata.com/resource/pubmed/chemical/glycogen synthase kinase 3 beta,
http://linkedlifedata.com/resource/pubmed/chemical/pituitary tumor-transforming...
|
pubmed:status |
MEDLINE
|
pubmed:month |
Aug
|
pubmed:issn |
1083-351X
|
pubmed:author | |
pubmed:issnType |
Electronic
|
pubmed:day |
26
|
pubmed:volume |
286
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
30047-56
|
pubmed:dateRevised |
2011-11-2
|
pubmed:meshHeading |
pubmed-meshheading:21757741-Animals,
pubmed-meshheading:21757741-Breast Neoplasms,
pubmed-meshheading:21757741-COS Cells,
pubmed-meshheading:21757741-Cercopithecus aethiops,
pubmed-meshheading:21757741-Female,
pubmed-meshheading:21757741-Glycogen Synthase Kinase 3,
pubmed-meshheading:21757741-HeLa Cells,
pubmed-meshheading:21757741-Humans,
pubmed-meshheading:21757741-Mitosis,
pubmed-meshheading:21757741-Neoplasm Proteins,
pubmed-meshheading:21757741-Phosphorylation,
pubmed-meshheading:21757741-Protein Stability,
pubmed-meshheading:21757741-SKP Cullin F-Box Protein Ligases
|
pubmed:year |
2011
|
pubmed:articleTitle |
Glycogen synthase kinase-3beta (GSK3beta) negatively regulates PTTG1/human securin protein stability, and GSK3beta inactivation correlates with securin accumulation in breast tumors.
|
pubmed:affiliation |
Departamento de Microbiología, Facultad de Biología, Universidad de Sevilla, Sevilla, Spain.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|